<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05032001</url>
  </required_header>
  <id_info>
    <org_study_id>protocol1</org_study_id>
    <nct_id>NCT05032001</nct_id>
  </id_info>
  <brief_title>ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT</brief_title>
  <official_title>ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT MEASURED BY BIOIMPEDANCE IN TYPE 2 DIABETES PATIENTS. Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metabolic Research Unit</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Metabolic Research Unit</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Weight control is an essential part of treatment for type 2 diabetes (T2D) patients. Weight&#xD;
      loss is associated with decreased haemoglobin A1c (A1c) levels. In particular, visceral fat&#xD;
      is accompanied by more alterations in glucose and lipid metabolism. Quantification of&#xD;
      visceral fat with bioimpedance (BIA) is closely related to measurement with computed axial&#xD;
      tomography. Different available oral antidiabetics cause weight loss and total body fat&#xD;
      (biguanides, DPP-4 inhibitors and SGLT-2 inhibitors), but it has only been shown that SLGT2&#xD;
      inhibitors decrease visceral fat. Therefore, the aim of this study is to determine whether&#xD;
      there is a difference in the amount of visceral fat measured with BIA in T2D patients between&#xD;
      three oral antidiabetic regimens after twelve weeks of treatment, to compare the effect on&#xD;
      visceral fat between metformin, DPP4 inhibitors and SGLT2 inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in visceral fat measured by bioimpedance in kg at weet twelve</measure>
    <time_frame>Baseline and week twelve</time_frame>
    <description>Bioimpedance is a confident method to measured visceral fat</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change from baseline in A1c level at week twelve</measure>
    <time_frame>Baseline and week twelve</time_frame>
    <description>Glycated hemoglobin percentage is the most reliable method to explain glycemic control in type 2 diabetes patients</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Abdominal Obesity</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 1.7-2.5mg per day during twelve weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformina + IDDP-4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 1.7-2.5mg per day plus Linagliptin 5mg per day or Sitagliptin 50-100mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformina + ISGLT-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 1.7-2.5mg per day plus Empaglifozin 10-25mg per day or Dapaglifozin 10mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biguanide, DPP4 inhibitors, SGLT2 inhibitors</intervention_name>
    <description>Oral antidiabetic treatment during twelve weeks</description>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>Metformina + IDDP-4</arm_group_label>
    <arm_group_label>Metformina + ISGLT-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients +18 years&#xD;
&#xD;
          -  Patients with visceral fat quantification by BIA at baseline and week twelve&#xD;
&#xD;
          -  Patients with body mass index &gt;25&#xD;
&#xD;
          -  Patients can swallow tablets&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients treated with other oral antidiabetic agents or insulin&#xD;
&#xD;
          -  Glomerular filtration rate less than 30 mL/min&#xD;
&#xD;
          -  Transaminemia greater than 2 times the upper reference value&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Malnutrition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Metabolic Research Unit</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78218</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Lee DH, Park KS, Ahn S, Ku EJ, Jung KY, Kim YJ, Kim KM, Moon JH, Choi SH, Park KS, Jang HC, Lim S. Comparison of Abdominal Visceral Adipose Tissue Area Measured by Computed Tomography with That Estimated by Bioelectrical Impedance Analysis Method in Korean Subjects. Nutrients. 2015 Dec 16;7(12):10513-24. doi: 10.3390/nu7125548.</citation>
    <PMID>26694460</PMID>
  </reference>
  <reference>
    <citation>Park KS, Lee DH, Lee J, Kim YJ, Jung KY, Kim KM, Kwak SH, Choi SH, Park KS, Jang HC, Lim S. Comparison between two methods of bioelectrical impedance analyses for accuracy in measuring abdominal visceral fat area. J Diabetes Complications. 2016 Mar;30(2):343-9. doi: 10.1016/j.jdiacomp.2015.10.014. Epub 2015 Oct 24.</citation>
    <PMID>26620129</PMID>
  </reference>
  <reference>
    <citation>Golay A. Metformin and body weight. Int J Obes (Lond). 2008 Jan;32(1):61-72. Epub 2007 Jul 24. Review.</citation>
    <PMID>17653063</PMID>
  </reference>
  <reference>
    <citation>Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007 Mar;9(2):194-205.</citation>
    <PMID>17300595</PMID>
  </reference>
  <reference>
    <citation>Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31. doi: 10.1210/jc.2011-2260. Epub 2012 Jan 11.</citation>
    <PMID>22238392</PMID>
  </reference>
  <reference>
    <citation>Sugiyama S, Jinnouchi H, Kurinami N, Hieshima K, Yoshida A, Jinnouchi K, Nishimura H, Suzuki T, Miyamoto F, Kajiwara K, Jinnouchi T. Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes. J Atheroscler Thromb. 2018 Jun 1;25(6):467-476. doi: 10.5551/jat.40873. Epub 2017 Dec 8.</citation>
    <PMID>29225209</PMID>
  </reference>
  <reference>
    <citation>Schork A, Saynisch J, Vosseler A, Jaghutriz BA, Heyne N, Peter A, Häring HU, Stefan N, Fritsche A, Artunc F. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovasc Diabetol. 2019 Apr 5;18(1):46. doi: 10.1186/s12933-019-0852-y.</citation>
    <PMID>30953516</PMID>
  </reference>
  <reference>
    <citation>Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2016 Jun;25(3):1057-73. doi: 10.1177/0962280215588241. Epub 2015 Jun 19.</citation>
    <PMID>26092476</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 21, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Metabolic Research Unit</investigator_affiliation>
    <investigator_full_name>Alonso Alberto Castro Arguelles</investigator_full_name>
    <investigator_title>Metabolic Research Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium-Glucose Transporter 2 Inhibitors</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
    <mesh_term>Biguanides</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

